FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression.
10.1007/s11684-022-0959-5
- Author:
Tianzhuo WANG
1
;
Huiying GUO
1
;
Lei ZHANG
1
;
Miao YU
1
;
Qianchen LI
1
;
Jing ZHANG
1
;
Yan TANG
1
;
Hongquan ZHANG
1
;
Jun ZHAN
2
Author Information
1. Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Beijing, 100191, China.
2. Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Beijing, 100191, China. Zhanjun@bjmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
FRMD6;
lung cancer;
mTOR pathway
- From:
Frontiers of Medicine
2023;17(4):714-728
- CountryChina
- Language:English
-
Abstract:
FRMD6, a member of the 4.1 ezrin-radixin-moesin domain-containing protein family, has been reported to inhibit tumor progression in multiple cancers. Here, we demonstrate the involvement of FRMD6 in lung cancer progression. We find that FRMD6 is overexpressed in lung cancer tissues relative to in normal lung tissues. In addition, the enhanced expression of FRMD6 is associated with poor outcomes in patients with lung squamous cell carcinoma (n = 75, P = 0.0054) and lung adenocarcinoma (n = 94, P = 0.0330). Cell migration and proliferation in vitro and tumor formation in vivo are promoted by FRMD6 but are suppressed by the depletion of FRMD6. Mechanistically, FRMD6 interacts and colocalizes with mTOR and S6K, which are the key molecules of the mTOR signaling pathway. FRMD6 markedly enhances the interaction between mTOR and S6K, subsequently increasing the levels of endogenous pS6K and downstream pS6 in lung cancer cells. Furthermore, knocking out FRMD6 inhibits the activation of the mTOR signaling pathway in Frmd6-/- gene KO MEFs and mice. Altogether, our results show that FRMD6 contributes to lung cancer progression by activating the mTOR signaling pathway.
